RE: To all Geniune investors6 Oct 2021 22:31
Polarean noted that it had a net cash balance of US$38.2mln at the end of June 2021 that should allow it to fund operations “comfortably” through its response to the CRL and the FDA review period.
In the meantime, it pledged to continue to collaborate with current and future research investigators in continued exploration of potential clinical applications of this technology, with its 9820 Xenon Polariser system installed in the world-renowned University of Texas MD Anderson Cancer Center in July and a follow-up order from the system from the University of British Columbia in May.